Trials / Recruiting
RecruitingNCT06656351
B-FREE Chronic Babesiosis Study
B-FREE Chronic Babesiosis Study: A Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients With Severe Fatigue
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- 60 Degrees Pharmaceuticals LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Phase 2 Open Label Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tafenoquine 100mg | Tafenoquine |
Timeline
- Start date
- 2025-11-18
- Primary completion
- 2027-02-01
- Completion
- 2027-09-01
- First posted
- 2024-10-24
- Last updated
- 2025-11-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06656351. Inclusion in this directory is not an endorsement.